platinum has been researched along with Cancer of the Urinary Tract in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (57.50) | 24.3611 |
| 2020's | 16 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adib, E; Alva, AS; Curran, C; Diamantopoulos, LN; Grivas, P; Jain, RK; Kazakova, V; Marandino, L; Merchan, JR; Necchi, A; Plastini, TM; Sonpavde, G; Su, C; Tandon, A | 1 |
| Banna, GL; Calabro, F; Emeribe, U; Fléchon, A; Hellmis, E; Hotte, SJ; Lee, JL; Lima, AR; Loriot, Y; Marabelle, A; Miranda, PAP; Oh, SM; Pouessel, D; Powles, T; Roubaud, G; Shin, SJ; Sonpavde, GP; Sternberg, CN; Vera-Badillo, FE; Zagonel, V | 1 |
| Lacouture, ME; O'Donnell, PH; Patel, AB; Rosenberg, JE | 1 |
| Adachi, T; Azuma, H; Egawa, S; Fukuokaya, W; Fukushima, T; Hashimoto, T; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Miki, J; Mori, K; Nakamori, K; Nakamura, K; Nishimura, K; Nishio, K; Ohno, Y; Shiroki, R; Takahara, K; Tsuduki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yanagisawa, T; Yano, Y; Yoshizawa, A | 1 |
| Abe, H; Fukuokaya, W; Hashimoto, M; Imai, Y; Ito, K; Iwatani, K; Kimura, S; Kimura, T; Koike, Y; Miki, J; Onuma, H; Oyama, Y; Tsuzuki, S; Urabe, F; Yamamoto, S; Yanagisawa, T | 1 |
| Goto, Y | 1 |
| Ito, K; Kita, Y; Kobayashi, T | 1 |
| Chen, R; Li, H; Wang, J; Wen, R; Zhou, J; Zhu, J | 1 |
| Bamias, A; Castellano, D; Drakaki, A; DuPree, K; Fléchon, A; Friedlander, T; Gomez-Roca, C; Joly Lobbedez, F; Lee, JL; Martin-Liberal, J; Michielin, F; Morales-Barrera, R; Moreno-Candilejo, I; Park, C; Powles, T; Rishipathak, D; Shemesh, CS; Shin, SJ; Steinberg, EE; Tosi, D; Williams, P; Young, F; Yuen, K | 1 |
| Lotan, Y; Meng, X | 1 |
| Petrylak, DP; Rosenberg, JE | 1 |
| Arkenau, HT; Chu, BC; Klein, AB; Nordstrom, BL; Oguz, M; Ouwens, M | 1 |
| Bellmunt, J; Ding, B; Hoffman-Censits, J; Kaiser, C; Pal, S | 1 |
| Hayakawa, N; Kikuchi, E | 1 |
| Alfred Witjes, J | 1 |
| Bokal, U; Mangaroski, D; Mencinger, M | 1 |
| Ohlmann, CH; Retz, M; Rexer, H | 1 |
| Fu, W; Goldberg, KB; Kim, G; Liu, Q; Maher, VE; Ning, YM; Palmby, T; Pazdur, R; Ricks, T; Suzman, D; Tang, S; Zhang, L | 1 |
| Biasoni, D; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Agarwal, N; Bamias, A; Baniel, J; Bellmunt, J; Berthold, DR; Bowles, DW; Crabb, S; Galsky, MD; Harshman, LC; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Plimack, ER; Pond, GR; Powles, T; Rosenberg, JE; Srinivas, S; Yu, EY | 1 |
| Hirayama, T; Ikeda, M; Irie, A; Iwamura, M; Koguchi, D; Matsuda, D; Matsumoto, K; Murakami, Y; Okuno, N; Taoka, Y; Utsunomiya, T | 1 |
| Di Nunno, V; Massari, F | 2 |
| Bellmunt, J; Hoffman-Censits, J; Kaiser, C; Pal, SK; Tayama, D; Zheng, H | 1 |
| Perez-Gracia, JL | 1 |
| Al-Ahmadie, H; Arcila, ME; Bajorin, DF; Bambury, RM; Bellmunt, J; Berger, MF; Bochner, BH; Bouvier, N; Boyd, ME; Cha, EK; Hyman, DM; Iyer, G; Jordan, E; Mullane, SA; Ostrovnaya, I; Roper, N; Rosenberg, JE; Solit, DB; Teo, MY; Zabor, EC | 1 |
| Agarwal, N; Tripathi, A | 1 |
| Itai, S; Izumi, K; Kadono, Y; Kitagawa, Y; Konaka, H; Machioka, K; Maolake, A; Mizokami, A; Namiki, M; Nohara, T; Takahashi, R; Yaegashi, H | 1 |
| Bellmunt, J; Choueiri, TK; Fay, AP; Leow, JJ; Mullane, SA; Riester, M; Rosenberg, J; Taplin, ME; Van Allen, E; Van Hummelen, P; Werner, L | 1 |
| Han, KS; Hong, SJ; Kim, KH | 1 |
| Bellmunt, J; Choueiri, TK; Guancial, EA; Kantoff, PW; Lis, RT; Loda, M; Mullane, SA; Rosenberg, J; Stack, EC; Werner, L | 1 |
| Di Palma, M; Guillot, A; Médioni, J; Spaeth, D; Théodore, C | 1 |
| Bochner, BH | 1 |
| Kikuchi, E; Kosaka, T; Mikami, S; Minamishima, YA; Miyajima, A; Miyazaki, Y; Mizuno, R; Niwa, N; Okada, Y; Otsuka, Y; Oya, M; Sabe, H; Suematsu, M; Tanaka, N; Uhlén, P | 1 |
| Chang, SS | 1 |
| Arranz, JÁ; Azrilevich, A; Baron, A; Bedke, J; Bracarda, S; Galsky, MD; Grimm, MO; Krishnan, S; Lambert, A; Necchi, A; Ohyama, C; Pal, S; Plimack, ER; Qu, X; Retz, M; Saci, A; Sharma, P; Siefker-Radtke, A; Vaena, D | 1 |
| Adamakis, I; Bamias, A; Chrisofos, M; Dimopoulos, MA; Fountzilas, G; Karadimou, A; Karavasilis, V; Murray, S; Nikitas, N; Pavlidis, N; Pectasides, D; Soupos, N; Tsiatas, M; Tsitoura, E | 1 |
| Daye, M; Guttenplan, JB; Safirstein, R | 1 |
1 review(s) available for platinum and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
7 trial(s) available for platinum and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Male; Platinum; Urinary Bladder Neoplasms; Urinary Tract; Urologic Neoplasms | 2022 |
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
Topics: Antibodies, Monoclonal; Carcinoma, Transitional Cell; Cell Adhesion Molecules; Female; Humans; Immunoconjugates; Male; Nectins; Platinum; Programmed Cell Death 1 Receptor; Urologic Neoplasms | 2022 |
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
[First-line therapy for locally advanced or metastatic urothelial carcinoma : A randomized, controlled phase III trial comparing pembrolizumab with or without platinum-based combination chemotherapy and chemotherapy only in patients with advanced or metas
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Platinum; Treatment Outcome; Urologic Neoplasms; Urothelium | 2017 |
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; United States; Urologic Neoplasms | 2018 |
Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gene Dosage; Humans; Male; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Survival Rate; TOR Serine-Threonine Kinases; Urologic Neoplasms | 2015 |
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Platinum; Prognosis; Survival Rate; Urologic Neoplasms | 2017 |
32 other study(ies) available for platinum and Cancer of the Urinary Tract
| Article | Year |
|---|---|
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Carcinoma, Transitional Cell; Female; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms | 2022 |
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Methotrexate; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2023 |
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Middle Aged; Platinum; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 2023 |
Enfortumab Vedotin Checks Urothelial Cancer.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2019 |
Critical treatment choices for patients with platinum-refractory urothelial carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Docetaxel; Double-Blind Method; Humans; Platinum; Ramucirumab; Urologic Neoplasms | 2020 |
Reply to F.E. Vera-Badillo et al.
Topics: Antibodies, Monoclonal; B7-H1 Antigen; Humans; Platinum; Urologic Neoplasms | 2020 |
Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Therapy; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Platinum; Proportional Hazards Models; Retrospective Studies; Urologic Neoplasms | 2020 |
Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Female; Humans; Male; Platinum; Renal Insufficiency; Urologic Neoplasms | 2020 |
Cabozantinib as a choice for platinum-refractory metastatic urothelial cancer.
Topics: Anilides; Carcinoma, Transitional Cell; Humans; Platinum; Pyridines; Urologic Neoplasms | 2020 |
Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Topics: B7-H1 Antigen; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Platinum; Prognosis; Urinary Bladder Neoplasms; Urologic Neoplasms | 2021 |
Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Prognosis; Survival Analysis; Urologic Neoplasms | 2021 |
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Drug Approval; Female; Humans; Male; Middle Aged; Platinum; Response Evaluation Criteria in Solid Tumors; Risk Assessment; Treatment Outcome; United States; United States Food and Drug Administration; Urologic Neoplasms; Urothelium | 2017 |
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Topics: Aged; B7-H1 Antigen; Carcinoma, Transitional Cell; Chromosomes, Human, X; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Platinum; Receptors, Androgen; Retrospective Studies; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Transitional Cell; Disease-Free Survival; Female; Humans; Male; Middle Aged; Platinum; Prognosis; Retrospective Studies; Treatment Outcome; Urologic Neoplasms | 2018 |
Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study.
Topics: Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Patient Selection; Platinum; Prognosis; Retrospective Studies; Urologic Neoplasms | 2018 |
Atezolizumab for platinum-treated metastatic urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2018 |
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2018 |
Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2018 |
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."
Topics: Carcinoma, Transitional Cell; DNA Damage; Humans; Mutation; Platinum; Urologic Neoplasms | 2018 |
Editorial Comment.
Topics: Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2018 |
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Humans; Platinum; United States; Urologic Neoplasms | 2019 |
Efficacy of tegafur-uracil in advanced urothelial cancer patients after the treatment failure of platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Platinum; Retrospective Studies; Tegafur; Uracil; Urologic Neoplasms | 2015 |
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Platinum; Predictive Value of Tests; Treatment Failure; Urologic Neoplasms; Urothelium; Vinblastine | 2015 |
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.
Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Transitional Cell; DNA Repair; DNA-Binding Proteins; Endonucleases; Fanconi Anemia Complementation Group Proteins; Female; Humans; Male; Membrane Proteins; Neoplasm Metastasis; Neoplasm Proteins; Platinum; Poly (ADP-Ribose) Polymerase-1; Prospective Studies; Rad51 Recombinase; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2016 |
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Platinum; Retrospective Studies; Urologic Neoplasms; Urothelium; Vinblastine | 2016 |
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2017 |
Acquired platinum resistance involves epithelial to mesenchymal transition through ubiquitin ligase FBXO32 dysregulation.
Topics: Aged; Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Muscle Proteins; Platinum; SKP Cullin F-Box Protein Ligases; Snail Family Transcription Factors; Urologic Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2016 |
Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Platinum; Urologic Neoplasms | 2016 |
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
Topics: Aged; Biomarkers, Pharmacological; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Single Nucleotide; Treatment Outcome; Urologic Neoplasms | 2012 |
Mutagenic activity and identification of excreted platinum in human and rat urine and rat plasma after administration of cisplatin.
Topics: Animals; Chromatography, High Pressure Liquid; Cisplatin; Humans; Male; Mutagenicity Tests; Platinum; Rats; Rats, Inbred Strains; Risk; Urologic Neoplasms | 1983 |